COMPARATIVE STUDY OF SERUM LIPID PROFILE IN OBESE TYPE 2 DIABETIC PATIENTS WITH OBESE NON DIABETIC PATIENTS

Introduction: Diabetic mellitus is a chronic metabolic disease characterized by hyperglycemia. Type 2 diabetes mellitus accounts for more than 90% of cases worldwide. Elevated HbA1c and dyslipidemia proportionately increases the risk of development of cardiovascular disease (CVD) which is the major cause of morbidity and mortality worldwide. Aims: To Study the correlation between glycated hemoglobin (HbA1c) and serum lipid profile in type 2 diabetic patients. Methods: This is a hospital based cross sectional study conducted at Nepalgunj medical college teaching hospital, which included 104 type 2 diabetic patients (54 males and 50 females).Venous blood samples were collected from all patients and serum was used for analyzing HbA1c, lipid profile panel and fasting blood glucose (FBG). DM was defined as per American diabetic association (ADA) criteria. Dyslipidemia was defined as per the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Guidelines. The data were analyzed using standard statistical methods, including SPSS 21. Results : Abnormal lipid parameters were demonstrated with increased Total Chloseterol (TC), Triglyceride (TG), Low density lipoprotein (LDL),Very low density lipoprotein (VLDL) and low High density lipoprotein (HDL) suggestive of dyslipidemia.HbA1c showed direct and significant correlation with TC,LDL,TG and VLDL. Patients with HbA1c > 7.0% had a significantly higher value of TC, LDL, TG and VLDL as compared to patients with HbA1c ≤7.0%.However, the significant difference in value of HDL-C was not found between two groups. Conclusion: Due to the strong correlation with lipid profile, HbA1c could be the ideal marker for predicting dyslipidemia in type 2 DM . Patients with higher HbA1c value and dyslipidemia should be considered as a very high risk group for CVD.

Download Full-text

The effect of different antihypertensive treatment protocoles on glycemic control and lipid profile in type 2 diabetic patients with microalbuminuria and stage 1 hypertension

Endocrine Abstracts ◽

10.1530/endoabs.49.ep533 ◽

2017 ◽

Author(s):

Muge Erek ◽

Alparslan Ersoy ◽

Canan Ersoy

Keyword(s):

Glycemic Control ◽

Lipid Profile ◽

Antihypertensive Treatment ◽

Diabetic Patients ◽

Type 2 Diabetic Patients ◽

Stage 1 ◽

Type 2 Diabetic

Download Full-text

Effect of atorvastatin on oxidative stress parameters and lipid profile in type 2 diabetic patients

IIUM Medical Journal Malaysia ◽

10.31436/imjm.v7i2.783 ◽

2020 ◽

Vol 7 (2) ◽

Author(s):

Najah RH ◽

Mohammad AAH ◽

Ammar RMR

Keyword(s):

Oxidative Stress ◽

Lipid Profile ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Diabetic Patients ◽

Type 2 Diabetic Patients ◽

Oxidative Stress Parameters ◽

Type 2 Diabetic ◽

Stress Parameters

Introduction: Evidence has long existed regarding the relationship between oxidative stress and diabetes. The present study was conducted to assess the effect of atorvastatin on selected oxidative stress parameters in the form of reduced glutathione (GSH), lipid peroxidation byproduct malondialdehyde (MDA) levels, glutathione –S- transferase (GST) activity and catalase (CAT) activity) and its effect on lipid profile (total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL) and very low density lipoprotein (VLDL) in dyslipidaemic type 2 diabetic patients . Materials and Methods: Fifty nine dyslipidaemic type 2 diabetic patients were included in this study. Full history was taken and general examination of patients was performed. Patients studied were taking glibenclamide (an oral hypoglycaemic drug) during the study as a treatment for their disease. These patients were followed up for 60 days and divided randomly into 2 groups. Group I (n = 31): no drug was given and served as dyslipidaemic diabetic control. Group II (n = 28): received atorvastatin tablets 20 mg once daily at night. Of the 59 Fifty patients, 46 completed the study while 13 patients withdrew. This is due to non compliance of the patients. Blood samples were drawn from the patients at the beginning and after 60 days of follow up between 8:30 & 10:30 am after at least 12-14 hours fast. Fasting blood glucose, lipid profile, selected oxidative stress parameters (GSH, MDA levels, GST and CAT activities) were measured. Renal and hepatic functions were also assessed. Results: This study revealed that: atorvastatin treatment increased serum GSH; reduced MDA levels significantly while did not significantly affect CAT and GST activity. In atorvastatin treatment, TC, TG, LDL and VLDL decreased significantly while HDL increased significantly. Conclusion: There was insignificant correlations between atorvastatin induced changes in the oxidation markers and the observed changes of the lipid profile.

Download Full-text